Pancreatic Ductal Adenocarcinoma Pipeline 2025: Groundbreaking Clinical Advancements by 80+ Global Leaders - DelveInsight | Featuring Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil P

With Pancreatic Ductal Adenocarcinoma reaching epidemic proportions globally and contributing significantly to comorbid conditions such as diabetes, cardiovascular disease, and certain cancers, there is a growing demand for safer, more effective treatment options. According to DelveInsight, the Pancreatic Ductal Adenocarcinoma pipeline comprises 80+ pharmaceutical and biotech companies actively developing 80+ therapeutic candidates targeting Pancreatic Ductal Adenocarcinoma. These therapies span various stages of clinical and non-clinical development, underscoring the intense innovation and commitment to addressing one of the most pressing public health challenges of our time.
DelveInsight's "Pancreatic Ductal Adenocarcinoma Pipeline Insight 2025" report provides a detailed and strategic evaluation of the ongoing R&D landscape. It covers clinical trial progression, emerging therapies, mechanisms of action, competitive positioning, and key company initiatives. The report serves as a crucial resource for stakeholders-including researchers, healthcare investors, and decision-makers, seeking insights into the evolving Pancreatic Ductal Adenocarcinoma Therapeutics Market and the breakthroughs shaping its future trajectory.

Explore the Cutting-Edge Landscape of Pancreatic Ductal Adenocarcinoma Drug Development @ https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key Takeaways from the Pancreatic Ductal Adenocarcinoma Pipeline Report

DelveInsight's Pancreatic Ductal Adenocarcinoma pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Pancreatic Ductal Adenocarcinoma treatment.
In April 2025, Nelson Yee announced a Phase II clinical trial to evaluate the effectiveness and safety of combining liposomal irinotecan (nal-IRI) with oxaliplatin, leucovorin, and 5-fluorouracil (FOLFOX-nal-IRI) for patients with locally advanced pancreatic cancer (LAPC).
In April 2025, InxMed (Shanghai) Co. Ltd revealed a multicenter, open-label, single-arm Phase Ib/II study consisting of two parts: a dose confirmation phase and a dose expansion phase. The dose confirmation phase aims to establish the recommended Phase II dose (RP2D) of IN10018 combined with standard chemotherapy (albumin-bound paclitaxel plus gemcitabine) and IN10018 combined with KN046 plus standard chemotherapy in patients with advanced pancreatic cancer. The dose expansion phase will further assess the safety and antitumor effectiveness of these combination therapies in this patient population.
Key Pancreatic Ductal Adenocarcinoma companies such as Cardiff Oncology, XOMA, Alphamab, Cantargia, RenovoRx, Syntrix Biosystems, Eucure Biopharma, Panbela Therapeutics, Jeil Pharmaceutical, Elicio Therapeutics, Cend Therapeutics, SignalChem Lifesciences, Bristol-Myers Squibb, AstraZeneca, REVOLUTION Medicines, Arcus Biosciences, ZielBio, Surface Oncology, Incyte Corporation, I-Mab Biopharma, Medicenna Therapeutics, Tarveda Therapeutics, and others are evaluating new drugs for Pancreatic Ductal Adenocarcinoma to improve the treatment landscape.
Promising Pancreatic Ductal Adenocarcinoma pipeline therapies in various stages of development include Onvansertib, Nadunolimab, Zimberelimab, and others.

Pancreatic Ductal Adenocarcinoma Overview:

Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, with a 5-year survival rate averaging below 10%. Most patients are diagnosed when the disease is already unresectable, locally advanced, or metastatic. The poor prognosis of PDAC stems from its complex and multifaceted nature. Early detection is challenging due to the absence of straightforward screening methods, and symptoms often emerge only after the cancer has advanced and spread to other organs. Treating pancreatic cancer is particularly difficult because of issues at both the genetic and cellular levels. The high degree of genetic mutations in pancreatic tumors leads to genomic instability, which significantly contributes to tumor progression and resistance to therapy.

Download the Pancreatic Ductal Adenocarcinoma sample report to know in detail about the Pancreatic Ductal Adenocarcinoma treatment market @ https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pancreatic Ductal Adenocarcinoma Pipeline Analysis
The Pancreatic Ductal Adenocarcinoma pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Pancreatic Ductal Adenocarcinoma Market.

Categorizes Pancreatic Ductal Adenocarcinoma therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Pancreatic Ductal Adenocarcinoma drugs under development based on:

Stage of development

Pancreatic Ductal Adenocarcinoma Route of administration

Target receptor

Monotherapy vs. combination therapy

Pancreatic Ductal Adenocarcinoma Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Pancreatic Ductal Adenocarcinoma Licensing agreements

Funding and investment activities supporting future Pancreatic Ductal Adenocarcinoma market advancement.

Unlock key insights into emerging Pancreatic Ductal Adenocarcinoma therapies and market strategies here: https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Pancreatic Ductal Adenocarcinoma Emerging Drugs

Onvansertib: Cardiff Oncology

Onvansertib is an oral, highly selective PLK1 inhibitor currently being tested in combination with standard-of-care treatments in clinical trials for conditions including KRAS-mutated metastatic colorectal cancer, metastatic pancreatic ductal adenocarcinoma, and metastatic castrate-resistant prostate cancer. These clinical programs, along with our overall development approach, aim to exploit tumor weaknesses to overcome resistance to treatment and provide better clinical outcomes than existing standard therapies.

Nadunolimab: Cantargia

Nadunolimab is a humanized, fucose-free monoclonal antibody developed by Cantargia for treating solid tumors, including non-small cell lung cancer (NSCLC) and pancreatic cancer. As a first-in-class anti-IL1RAP antibody, Nadunolimab is currently being tested alongside standard chemotherapy or checkpoint inhibitors in five phase I/II clinical trials, primarily focusing on PDAC and NSCLC. It works by inducing antibody-dependent cellular cytotoxicity (ADCC) and inhibiting signaling of both IL-1α and IL-1β, thereby reducing the immune-suppressive tumor microenvironment and overcoming chemotherapy resistance.

Zimberelimab: Arcus Biosciences

Zimberelimab is a monoclonal antibody targeting PD-1 that helps restore T-cell antitumor activity. Arcus licensed zimberelimab to develop precision combination therapies. Its most advanced trial is a Phase 2 study for first-line metastatic non-small cell lung cancer, testing zimberelimab alongside domvanalimab (an anti-TIGIT antibody) and etrumadenant (a dual A2a/A2b adenosine receptor antagonist). Additionally, zimberelimab is being investigated as a monotherapy in a Phase 1b trial for biomarker-selected cancers lacking approved anti-PD-1 treatments, with the goal of advancing innovative therapies for patients in need.

Pancreatic Ductal Adenocarcinoma Pipeline Therapeutic Assessment

Pancreatic Ductal Adenocarcinoma Assessment by Product Type
• Mono
• Combination
• Mono/Combination

Pancreatic Ductal Adenocarcinoma By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Pancreatic Ductal Adenocarcinoma Assessment by Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Pancreatic Ductal Adenocarcinoma Assessment by Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Download sample pages to get an in-depth assessment of the emerging Pancreatic Ductal Adenocarcinoma therapies and key Pancreatic Ductal Adenocarcinoma companies: https://www.delveinsight.com/sample-request/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. Pancreatic Ductal Adenocarcinoma Current Treatment Patterns
4. Pancreatic Ductal Adenocarcinoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Ductal Adenocarcinoma Late-Stage Products (Phase-III)
7. Pancreatic Ductal Adenocarcinoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Ductal Adenocarcinoma Discontinued Products
13. Pancreatic Ductal Adenocarcinoma Product Profiles
14. Pancreatic Ductal Adenocarcinoma Key Companies
15. Pancreatic Ductal Adenocarcinoma Key Products
16. Dormant and Discontinued Products
17. Pancreatic Ductal Adenocarcinoma Unmet Needs
18. Pancreatic Ductal Adenocarcinoma Future Perspectives
19. Pancreatic Ductal Adenocarcinoma Analyst Review
20. Appendix
21. Report Methodology

Request the sample PDF to get detailed insights about the Pancreatic Ductal Adenocarcinoma pipeline reports offerings:https://www.delveinsight.com/report-store/pancreatic-ductal-adenocarcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact info:

Kritika Rehani
Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.